ICON

Clinical trial
#AI #Clinical trials #ICON

Partnership set to make therapies ‘reach patients sooner’ 

A new partnership could accelerate clinical trials and bring therapies to patients sooner.  Clinical research organisation ICON has partnered with Advarra to introduce a new ‘research-ready’ site network model for clinical trials, set to address major bottlenecks.  The partnership will integrate ICON’s global clinical trial solutions and… Read More

#News

Chinese flag
#AI #Antibody drug conjugate (ADC) #Biotech #China #ICON

China becoming dominant force in biotech sector, survey says 

China is emerging as a ‘global innovation powerhouse’, according to clinical research organisation ICON.  ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.  According to the… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #ICON #Public health

ICON on the real-world integration of AI in drug R&D

DDW’s Megan Thomas speaks with ICON’s IT Director, Marco Heldoorn, about leveraging artificial intelligence (AI) to enhance efficiency, decision-making, and patient outcomes across the drug development lifecycle, from early feasibility to post-marketing. MT: Could you provide an overview of your findings when it comes to drug development and AI? TO:… Read More

#Business & Investment #Exclusive Content

#Biotechnology #Cardiometabolic diseases #Drug development #Drug discovery #ICON #Pharmaceuticals #Survey

More efficient next-gen obesity clinical trials needed, says survey

ICON has released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe, focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. Read More

#News

Covid-19 vaccines
#Covid-19 #Covid-19 vaccine #ICON #Immunology / Virology & Vaccines #Phase II trial

Partners to execute next generation Covid-19 vaccines clinical trial

ICON, a healthcare intelligence and clinical research organisation, with the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, will execute a clinical trial to evaluate the effectiveness of next-generation Covid-19… Read More

#News

ESG cloud icon green earth concept for environment
#Clinical trials #Diversity #ESG #Healthcare #ICON

Exclusive insight from ICON Cares 2022 ESG Report 

ICON, a healthcare intelligence and clinical research organisation, recently released its ICON Cares 2022 Environmental, Social and Governance (ESG) Report. Diarmaid Cunningham, Chief Administrative Officer at ICON, shares insight with DDW.  At ICON, we engage with our key stakeholders through a variety of methods and the environmental,… Read More

#Business & Investment #Exclusive Content #Regulatory

Dermatology patient
#Clinical trial design #Clinical trials #Decentralised clinical trials #ICON #LEO Pharma

LEO partners with ICON to offer patient-centric dermatology trials

LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges. Read More

#News